3 active not recruiting, 3 terminated, 3 unknown, 2 completed. 13 Phase 2, 9 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 13 | Active not recruiting 3, Terminated 3, Unknown 3, Completed 2, Recruiting 1, Withdrawn 1 |
| Phase 1 | 9 | Unknown 3, Active not recruiting 2, Terminated 2, Completed 1, Recruiting 1 |
Follow Medullary Thyroid Cancer: new trials by email Literature Review of Medullary Thyroid Cancer trials Research Report on Medullary Thyroid Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors Tarlatamab, Concurrent Radiation Therapy, Sequential Radiation therapy - Melanoma, Medullary Thyroid Cancer | Phase 1 / Phase 2 | Recruiting | University of Arizona | 30 | 2025-09-08 | 2026-10-06 |
| A Study of TY-1091 in Patients With Advanced Solid Tumors TY-1091 - RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer | Phase 1 / Phase 2 | Unknown | TYK Medicines, Inc | 248 | 2023-04-24 | 2024-01-30 |
| Phase I/II Study of SY-5007, a RET Inhibitor, in Patients With RET-altered Advanced Solid Tumor SY-5007 - Non-Small Cell Lung Cancer, Medullary Thyroid Cancer | Phase 1 / Phase 2 | Unknown | Shouyao Holdings (Beijing) Co. LTD | 184 | 2021-04-23 | 2023-04-12 |
| A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation Selpercatinib - Solid Tumor, Medullary Thyroid Cancer | Phase 2 | Active not recruiting | Eli Lilly and Company | 77 | 2020-03-16 | 2026-08-07 |
| Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations TPX-0046 - Non Small Cell Lung Cancer, Medullary Thyroid Cancer | Phase 1 / Phase 2 | Terminated | Turning Point Therapeutics, Inc. | 41 | 2019-12-06 | 2024-06-13 |
| Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer Ponatinib - Medullary Thyroid Cancer | Phase 2 | Withdrawn | Antonio Fojo | 2019-07-26 | 2021-10-13 | |
| A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors Selpercatinib - Medullary Thyroid Cancer, Infantile Myofibromatosis | Phase 1 / Phase 2 | Active not recruiting | Eli Lilly and Company | 36 | 2019-06-13 | 2026-01-06 |
| A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) LOXO-292 - Non-Small Cell Lung Cancer, Medullary Thyroid Cancer | Phase 1 / Phase 2 | Active not recruiting | Eli Lilly and Company | 857 | 2017-05-02 | 2026-04-16 |
| Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors pralsetinib (BLU-667) - RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer | Phase 1 / Phase 2 | Completed | Hoffmann-La Roche | 590 | 2017-03-17 | 2025-05-31 |
| Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors Rovalpituzumab tesirine, Dexamethasone - Malignant Melanoma, Medullary Thyroid Cancer | Phase 1 / Phase 2 | Terminated | AbbVie | 200 | 2016-09-23 | 2020-10-19 |
| The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer CASAD - Diarrhea, Medullary Thyroid Cancer | Phase 1 / Phase 2 | Unknown | Salient Pharmaceuticals Incorporated | 10 | 2012-11-01 | 2012-12-03 |
| SOM230 Alone or in Combination With RAD001 in Patients With Medullary Thyroid Cancer SOM230 alone or in combination with RAD001. - Medullary Thyroid Cancer | Phase 2 | Completed | Federico II University | 19 | 2012-02-01 | 2016-04-25 |
| An Initial Study of Lithium in Patients With Medullary Thyroid Cancer Lithium carbonate - Medullary Thyroid Cancer | Phase 2 | Terminated | University of Wisconsin, Madison | 5 | 2008-01-01 | 2019-12-09 |
Carcinoma, Medullary (13) · Carcinoma, Non-Small-Cell Lung (7) · Thyroid Neoplasms (5) · Lung Neoplasms (4) · Neoplasms (4) · Bronchial Neoplasms (3) · Carcinoma, Bronchogenic (3) · Colonic Neoplasms (3) · Endocrine Gland Neoplasms (3) · Endocrine System Diseases (3) · Head and Neck Neoplasms (3) · Lung Diseases (3) · Neoplasms by Site (3) · Respiratory Tract Diseases (3) · Respiratory Tract Neoplasms (3)
Neoplasms, Ductal, Lobular, and Medullary (13) · Adenocarcinoma (12) · Carcinoma (12) · Carcinoma, Neuroendocrine (12) · Neoplasms by Histologic Type (12) · Neoplasms, Germ Cell and Embryonal (12) · Neoplasms, Glandular and Epithelial (12) · Neoplasms, Nerve Tissue (12) · Neuroectodermal Tumors (12) · Neuroendocrine Tumors (12) · Neoplasms (9) · Neoplasms by Site (5) · Bronchial Neoplasms (4) · Carcinoma, Bronchogenic (4) · Lung Diseases (4)
selpercatinib (3) · Calcium Aluminosilicate (1) · Dexamethasone (1) · Everolimus (1) · Lithium Carbonate (1) · pasireotide (1) · ponatinib (1) · pralsetinib (1) · rovalpituzumab tesirine (1)
Eli Lilly and Company (3) · AbbVie (1) · Antonio Fojo (1) · Federico II University (1) · Hoffmann-La Roche (1) · Salient Pharmaceuticals Incorporated (1) · Shouyao Holdings (Beijing) Co. LTD (1) · TYK Medicines, Inc (1) · Turning Point Therapeutics, Inc. (1) · University of Arizona (1) · University of Wisconsin, Madison (1)
United States (8) · China (4) · Italy (4) · South Korea (4) · France (3) · Germany (3) · Spain (3) · United Kingdom (3) · Australia (2) · Canada (2) · Denmark (2) · Hong Kong (2) · Japan (2) · Singapore (2) · Taiwan (2)
Annamaria Colao (1) · Antonio Fojo, MD (1) · Charles Hsu, MD (1) · Herbert Chen, MD (1) · Ricklie Julian, MD (1) · Yinghui Sun, PhD (1)
PMID 37934000, PMID 29572709, PMID 32372416, PMID 32846060, PMID 32846061, PMID 34088726, PMID 34118197, PMID 34118198, PMID 35715405, PMID 35923928, PMID 35930972, PMID 35962206, PMID 36062046, PMID 36108661, PMID 36122315, PMID 36657661, PMID 37265412, PMID 37282666, PMID 37315261, PMID 37655205, PMID 37916501, PMID 38009200, PMID 38661071, PMID 39085487, PMID 39094065, PMID 39471424, PMID 39489747, PMID 39759832, PMID 39983053, PMID 40639400, PMID 41886723, PMID 42874021
2016 (1), 2017 (1), 2019 (1), 2023 (1)